(W412) Pyoderma Gangrenosum: A Difficult Entity to Diagnosis and Manage (AP w/ Pharm)
- Room: Ballroom E-J
- Session Number:W412
Monday, May 22, 2017: 4:20 PM - 5:20 PM
Pyoderma gangrenosum can be challenging to diagnose and manage. This session will provide a review of the pathogenesis, clinical features, pathology, and associated diseases of the four major clinical forms. As pyoderma gangrenosum is a diagnosis of exclusion, a brief overview of the differential diagnoses for ulcerative skin conditions will be highlighted. While there is neither specific or uniform treatment for pyoderma gangrenosum, there are a myriad of local and systemic immunosuppressive therapies available to the clinician to aid in treating this neutrophilic dermatosis. An overview of the mechanism of action, pharmacokinetics, indications, contraindications, dosing regimen, monitoring guidelines, and adverse effects of local and systemic immunosuppressive medications will be provided. This course will equip the clinician with the clinical guidelines for the selection and monitoring of immunosuppressive therapies to support the healing of pyoderma gangrenosum ulcers.
Learning ObjectivesThe participant will have increased knowledge regarding the mechanism of action, pharmacokinetics, indications, contraindications, dosing regimen, monitoring guidelines, and adverse effects of topical tacrolimus, intralesional kenaolog, prednisone, cyclosporine, methotrexate, infliximab, azathioprine, IV IG, and mycophenalate mofetil to aid the clinician in the selection and monitoring of immunosuppressive therapy to support the healing of pyoderma gangrenosum ulcers.